Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA granted traditional approval to pirtobrutinib, marketed as Jaypirca, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor.
The decision followed accelerated approval in 2023 for a narrower later-line population.
Traditional approval matters because it signals that FDA judged confirmatory evidence sufficient for the indication.
Why It Matters
Conversion from accelerated to traditional approval is an important checkpoint for oncology evidence quality.
What to Watch
Watch sequencing after covalent BTK inhibitors and uptake in relapsed CLL/SLL care.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDACLLSLLHematology